Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 5/2008

01.05.2008 | Gastrointestinal Oncology

Two Subtypes of Mucinous Adenocarcinoma of The Colorectum: Clinicopathological and Genetic Features

verfasst von: Sarli Leopoldo, MD, Bottarelli Lorena, BScD, Azzoni Cinzia, BScD, Di Cola Gabriella, BScD, PhD, Barilli Angela Luciana, MathD, Costi Renato, MD, PhD, Mazzeo Antonio, MD, Salvemini Carlo, MD, Porrini Cristina, MD, Cecchini Stefano, MD, Taglia Maurizio, MD, Roncoroni Luigi, MD, Bordi Cesare, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

This work is aimed at comparing mucinous colorectal adenocarcinomas (MUC) and non-mucinous colorectal adenocarcinomas (non-MUC), and at verifying the existence of two different subgroups of MUC, in terms of clinicopathological features, chromosomal alterations, and outcome, in a geographical area where mucinous colorectal cancer resulted as being very frequent.

Methods

One hundred and fifty-six unselected patients who underwent curative colorectal resection for sporadic colorectal cancer over a 4-year period were evaluated for histological classification as to MUC and non-MUC subtype, for microsatellite instability (MSI) using six microsatellite markers, and for the presence of p27, Fhit, and cyclooxygenase-2 (Cox-2). Molecular data, immunohistochemical results, recurrence frequency, and patient survival were analyzed statistically in relation to histological subtypes.

Results

MUC accounted for 38.5% of all colorectal carcinomas. Compared to non-MUCs, MUCs were more frequently located in the proximal colon (p < 0.001), and more frequently showed MSI phenotype (p < 0.001), altered protein expression of hMlh1 (p = 0.030), Fhit (p <0.001), and p27 (p < 0.001). Compared to MUC with microsatellite-stable (MSS) phenotype, MUC with MSI more frequently resulted as being located in the proximal colon (p = 0.013), and more frequently showed altered expression of hMlh1 (p < 0.001), hMsh2 (p = 0.008), Fhit (p < 0.001), and p27 (p = 0.015). Significantly better survival of patients with proximal MUC (p = 0,012), with MSI MUC (p = 0.017), and with MUC with altered p27 expression (p = 0.02).

Conclusion

The results of the present study confirm that MUC represents distinct clinicopathological and genetic features as compared to non-mucinous tumors and support the hypothesis that MUC includes two subtypes with different genetic pathways and behavior.
Literatur
1.
Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer 1976; 37: 1891–90PubMedCrossRef
2.
Nissan A, Guillem JG, Paty PB, et al. Signet-ring cell carcinoma of the colon and rectum: a matched control study. Dis Colon Rectum 1999; 42: 1176–80PubMedCrossRef
3.
4.
Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985; 72: 715–8PubMedCrossRef
5.
Green JB, Timmcke AE, Mitchell WT, et al. Mucinous carcinoma-just another colon cancer? Dis Colon Rectum 1993; 36: 49–54PubMedCrossRef
6.
Secco GB, Fardelli R, Campora E, et al. Primary mucinous adenocarcinomas and signet-ring cell carcinomas of the colon and rectum. Oncology 1994; 51: 30–4PubMedCrossRef
7.
Consorti F, Lorenzotti A, Midiri G, et al. Prognsotic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 2000; 73: 70–4PubMedCrossRef
8.
Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003; 46; 160–7PubMedCrossRef
9.
Berg JW, Godwin JD 2nd. The epidemiologic pathology of carcinomas of the large bowel. J Surg Oncol 1974; 6: 381–400PubMedCrossRef
10.
Pihl E, Nairn RC, Hughes ES, et al. Mucinous colorectal carcinoma: immunopathology and prognosis. Pathology 1980; 41: 439–47CrossRef
11.
Minsky BD, Mies C, Rich TA, et al. Colloid carcinoma of the colon and rectum. Cancer 1987; 60: 3103–12PubMedCrossRef
12.
Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. J Clin Pathol 1988; 41: 1068–72PubMedCrossRef
13.
Du W, Mah JT, Lee J, et al. Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum 2004; 47: 78–85PubMedCrossRef
14.
15.
Zhang H, Evertsson S, Sun X. Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol 1999; 14: 1057–61PubMed
16.
Wu CS, Tung SY, Chen PC, et al. Clinicopathological study of colorectal mucinous carcinoma in Taiwan: a multivariate analysis. J Gastroenterol Hepatol 1996; 11: 77–81PubMedCrossRef
17.
Sundbad AS, Paz RA. Mucinous carcinoma of the colon and the rectum and their relation to polyps. Cancer 1982; 50: 2504–9CrossRef
18.
Berovalis P, Harlaftis N. Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol 2004; 8 Suppl: s123–5
19.
Kondo T, Masuda H, Abe Y, et al. Two subtypes in colorectal mucinous carcinoma in relation to microsatellite instability. Hepatogastroenterology 2002; 49: 660–3
20.
Liu XP, Sato T, Oga A, et al. Two subtypes of mucinous colorectal carcinoma characterized by laser scanning cytometry and comparative genomic hybridization. Int J Oncol 2004; 25: 615–25PubMed
21.
Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386: 623–7PubMedCrossRef
22.
Martin L, Assem M, Piard F. Are there several types of colorectal carcinomas? Correlations with genetic data. Eur J Cancer Prev Dec 1999;8(Suppl 1): S13–S20
23.
Haydon AM, J.R. J. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002;3: 83–8
24.
Arribas R, Ribas M, Risques RA, et al. Prospective assessment of allelic losses at 4p14–16 in colorectal cancer: two mutational patterns and a locus associated with poorer survival. Clin Cancer Res 1999;5: 3454–9PubMed
25.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61: 759–67PubMedCrossRef
26.
Tejpar S, Van Cutsem E. Molecular and genetic defects in colorectal tumorigenesis. Best Pract Res Clin Gastroenterol 2002;16: 171–85PubMedCrossRef
27.
Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91: 1295–303PubMedCrossRef
28.
Modrich P. Mechanisms and biological effects of mismatch repair. Annu Rev Genet 1991;25: 229–53PubMedCrossRef
29.
Sarli L, Bottarelli L, Azzoni C, et al. Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer 2004;40: 1581–1588PubMedCrossRef
30.
Loda M, Cukor B, Tam SW, Lavin et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3: 231–4
31.
Sheehan KM, Sheahan K, O’Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282: 1254–7PubMedCrossRef
32.
Sarli L, Bottarelli L, Bader G, et al. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosoma 18q. Dis Colon Rectum 2004; 47: 1467–82PubMedCrossRef
33.
Jass JR, Sobin LH. Histological typing of intestinal tumours. 2nd ed. Berlin, Germany: Springer-Verlag, 1989
34.
Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322352–8
35.
Dent OF, Chapuis PH, Bokey EL, et al. Methodology and reporting in studies of local recurrence after curative excision of the rectum for cancer. Br J Surg 2001;88: 1476–80PubMedCrossRef
36.
Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331: 213–221PubMedCrossRef
37.
Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260: 816–9PubMedCrossRef
38.
Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91: 1295–303PubMedCrossRef
39.
Beckmann MW, Picard F, An HX, et al. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 1996;73: 1220–1226PubMed
40.
Mueller JD, Haegle N, Keller G, et al. Loss of heterozygosity and microsatellite instability in de novo versus ex-adenoma carcinomas of the colorectum. Am J Pathol 1998;153: 1977–84PubMed
41.
Ward R, Meagher A, Tomlinson I, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001;48: 821–829PubMedCrossRef
42.
Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998;58: 1713–8PubMed
43.
Peiro´ G, Diebold J, Lohse P, et al. Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Human Pathol 2002;33: 347–54CrossRef
44.
Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50: 401–23PubMedCrossRef
45.
Kang SM, Maeda K, Onoda N, et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1977; 74: 502–7CrossRef
46.
Boland GP, Butt IS, Prasad R, et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90: 423–9PubMedCrossRef
47.
Suma KS, Nirmala V. Mucinous component in colorectal carcinoma-prognostic significance: a study in a south Indian population. J Surg Oncol 1992;51: 60–4PubMedCrossRef
48.
Nozoe T, Anai H, Nasu S, et al. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol 2000; 75: 103–7PubMedCrossRef
49.
50.
Sasaki O, Atkin WS, Jass JR. Mucinous carcinoma of the rectum. Histopathology 1987;11: 259–72PubMedCrossRef
51.
Connelly JH, Robey-Cafferty SS, Cleary KR. Mucinous carcinomas of the colon and rectum. An analysis of 62 stage B and C lesions. Arch Pathol Lab Med 1991;115: 1022–5PubMed
52.
Okuno M, Ikehara T, Nagayama M, et al. Mucinous colo-rectal carcinoma: clinical pathology and prognosis. Am Surg. 1988;54: 681–5PubMed
53.
Odone V, Chang L, Caces J, et al. The natural history or colorectal carcinoma in adolescents. Cancer 1982; 49: 1716–20PubMedCrossRef
54.
de Mascarel A, Coindre JM, de Mascarel I, et al. The prognostic significance of specific histologic features of carcinoma of the colon and rectum. Surg Gynecol Obstet 1981; 153: 511–4PubMed
55.
Isono K, Saitoh T, Sato H, Nakano K. Histopathological studies on the prognosis of rectal carcinoma, especially on the comparison with that of gastric carcinoma. Gan No Rinsho 1975; 21: 905–9
56.
Hanski C. ls mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer 1995;72: 1350–6PubMed
57.
Akino F, Mitomi H, Nakamura T, et al. High apoptotic and low epithelial cell proliferation with underexpression of p21waf1/cip1 and p27kip1 of mucinous carcinomas of the colorectum. Am J Clin Pathol 2002; 117: 908–15 PubMedCrossRef
58.
Messerini L, Ciantelli M, Baglioni S, et al. Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. Human Pathol 1999; 30: 629–34CrossRef
59.
Tenjo T, Toyoda M, Okuda J, et al. Prognostic significance of p27kip1 protein expression and spontaneous apoptosis in patients with colorectal adenocarcinoma. Oncology 2000; 58: 45–51PubMedCrossRef
60.
Zhang H, Sun XF. Loss of p27 expression predicts poor prognosis in patients with Dukes’ B stage or proximal colorectal cancer. Int J Oncol 2001; 19: 49–52PubMed
61.
Cheng JD, Werness BA, Babb JS, et al. Paradoxical correlation of cyclin-dependent kinase inhibitors p21 waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res 1999; 5: 1057–62PubMed
62.
Kobayashy M, Shiraishi T, Tonouchi H, et al. 5-FU improves p27-related poor prognosis in patients with Astler-Coller B2-C colorectal carcinoma. Oncol Rep 2002; 9: 29–33
63.
McKay JA, Douglas JJ, Ross VG, et al. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 2002; 196: 386–93PubMedCrossRef
64.
Azzoni C, Bottarelli L, Campanini N, et al. Distinct molecular patterns on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis 2007;22: 115–26PubMedCrossRef
65.
Del Rio M, Molina F, Bascoul-Mollevi C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, Fluorouracil, and irinotecan. J Clin Oncol 2007; 25: 773–80PubMedCrossRef
Metadaten
Titel
Two Subtypes of Mucinous Adenocarcinoma of The Colorectum: Clinicopathological and Genetic Features
verfasst von
Sarli Leopoldo, MD
Bottarelli Lorena, BScD
Azzoni Cinzia, BScD
Di Cola Gabriella, BScD, PhD
Barilli Angela Luciana, MathD
Costi Renato, MD, PhD
Mazzeo Antonio, MD
Salvemini Carlo, MD
Porrini Cristina, MD
Cecchini Stefano, MD
Taglia Maurizio, MD
Roncoroni Luigi, MD
Bordi Cesare, MD
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9757-1

Weitere Artikel der Ausgabe 5/2008

Annals of Surgical Oncology 5/2008 Zur Ausgabe

Bone and Soft Tissue Sarcomas

Evidence-Guided Surgical Management of GIST: Beyond a Simple Case of Benign and Malignant

Hepatic and Pancreatic Tumors

Survival After Pancreatectomy With Major Arterial Resection and Reconstruction

Hepatic and Pancreatic Tumors

Microvascular Invasion in Patients with Hepatocellular Carcinoma and Its Predictable Clinicopathological Factors

Erratum

Factors Predictive of Nonsentinel Lymph Node Involvement and Clinical Outcome in Melanoma Patients With Metastatic Sentinel Lymph Node

Gastrointestinal Oncology

Pseudomyxoma Peritonei: Is Disease Progression Related to Microbial Agents? A Study of Bacteria, MUC2 and MUC5AC Expression in Disseminated Peritoneal Adenomucinosis and Peritoneal Mucinous Carcinomatosis

Hepatic and Pancreatic Tumors

Surgical Treatment of Hepatocellular Carcinoma beyond Milan Criteria. Results of Liver Resection, Salvage Transplantation, and Primary Liver Transplantation

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.